{'fraction_non_alphanumeric': 0.02366412213740458, 'fraction_numerical': 0.024427480916030534, 'mean_word_length': 5.364077669902913, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
EPOS 2020: What’s new for physician practitioners?

The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 also abbreviated to EPOS 2020, is the new edition
of the European document devoted to the broadly understood topic of inflammation of the nasal mucosa and paranasal
sinuses. The first edition appeared in 2005, followed by further editions in 2007 and 2012. In February 2020, we received
the latest version, extended, somewhat modified, expanded to include the latest research and meta-analysis in the fields
of: rhinology, rhinosurgery, epidemiology and reports on comorbidities. A completely new division of chronic sinusitis was
presented. Recommendations based on the highest quality evaluations, resulting from the publication of the last eight years,
also introduce a system based on integrated care pathways, or ICP in sinusitis. Chapters on pediatric aspects and sinus surgery
have been expanded. EPOS 2020 is addressed not only to doctors, but also to: nurses, pharmacists, other healthcare workers,
as well as patients themselves, who often make the first attempts at treatment with OTC preparations, frequently based on
the recommendations of pharmacists. The latest EPOS also specifies directions for further lines of research in the broadly
understood field of rhinosinusitis.

